IL17A and myeloid sarcoma: This opens novel therapeutic avenues; a soluble version of IL17RC is currently being developed as a potential drug for MS [80], while another clinical trial (NCT01051817) is investigating the effects of a monoclonal antibody that targets IL17A (AIN457).